CHGCY:OTC-Chugai Pharmaceutical Co., Ltd (USD)

COMMON STOCK | Drug Manufacturers-General | OTC

Last Closing Price

USD 19.53

Change

-0.22 (-1.11)%

Market Cap

USD 65.49B

Volume

0.05M

Average Target Price

N/A
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, marketing, and distribution of prescription medicines in Japan and internationally. The company's products for oncology primarily include Avastin, Herceptin, Rituxan, Alecensa, Perjeta, Xeloda, Tarceva, Kadcyla, Zelboraf, Neutrogin, Tecentriq, and Gazyva; bone and joint diseases/autoimmune diseases comprise Actemra, Edirol, Suvenyl, and Bonviva; renal diseases consist of Mircera and Oxarol; and other diseases comprise Tamiflu, CellCept, Copegus, and Hemlibra. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group and Genentech; and co-development agreements with Taisho Pharmaceutical Co., Ltd. and Nippon Shinyaku Co., Ltd. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-06-18 )

Largest Industry Peers for Drug Manufacturers-General

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
RHHBF Roche Holding AG

N/A

USD333.79B 22.88 14.62
RHHBY Roche Holding AG

-0.41 (-0.86%)

USD331.71B 20.66 14.62
RHHVF Roche Holding AG

-0.10 (-0.03%)

USD326.99B 20.45 14.62
NVSEF Novartis AG

N/A

USD210.90B 26.74 14.12
AZNCF AstraZeneca PLC

-0.92 (-0.79%)

USD153.07B 38.47 18.77
SNYNF Sanofi

-3.18 (-2.91%)

USD136.83B 9.32 9.08
GLAXF GlaxoSmithKline plc

-0.84 (-4.04%)

USD104.66B 14.17 13.19
CHGCF Chugai Pharmaceutical Co., Ltd

N/A

USD66.41B 34.95 0.22
BAYRY Bayer Aktiengesellschaft

-0.24 (-1.47%)

USD63.07B 8.67 10.06
BAYZF Bayer Aktiengesellschaft

-0.36 (-0.56%)

USD62.90B 8.75 10.06

ETFs Containing CHGCY

Symbol Name Weight Mer Price(Change) Market Cap
JPMV iShares Edge MSCI Min Vol.. 0.00 % 0.30 %

N/A

USD0.02B
SUJA:LSE iShares IV Public Limited.. 0.00 % 0.20 %

-6.63 (-1.26%)

USD0.69B
SUJP:LSE iShares MSCI Japan SRI UC.. 0.00 % 0.20 %

-0.13 (-1.74%)

USD0.69B

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-General)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -26.58% 9% F 10% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -26.58% 8% F 10% F
Trailing 12 Months  
Capital Gain -25.42% 8% F 11% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -25.42% 8% F 10% F
Trailing 5 Years  
Capital Gain 225.57% 97% A+ 77% C+
Dividend Return 0.70% 15% F 5% F
Total Return 226.26% 97% A+ 77% C+
Average Annual (5 Year Horizon)  
Capital Gain 44.72% 94% A 71% C-
Dividend Return 0.01% 4% F 1% F
Total Return 44.73% 91% A- 71% C-
Risk Return Profile  
Volatility (Standard Deviation) 31.45% 35% F 64% D
Risk Adjusted Return 142.20% 91% A- 99% A+
Market Capitalization 65.49B 78% C+ 98% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-General)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 33.96 24% F 24% F
Price/Book Ratio 7.53 23% F 20% F
Price / Cash Flow Ratio 0.32 64% D 44% F
EV/EBITDA 0.22 72% C- 76% C
Management Effectiveness  
Return on Equity 22.93% 71% C- 90% A-
Return on Invested Capital 23.75% 81% B- 85% B
Return on Assets 16.71% 100% A+ 97% A+
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.67 28% F 60% D-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.